Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sagimet Biosciences (SGMT) Cash from Operations (2023 - 2024)

Sagimet Biosciences (SGMT) has 2 years of Cash from Operations data on record, last reported at 11024000.0 in Q4 2024.

  • For Q4 2024, Cash from Operations fell 55.64% year-over-year to 11024000.0; the TTM value through Dec 2024 reached 42435000.0, down 78.55%, while the annual FY2025 figure was 45650000.0, 7.58% down from the prior year.
  • Cash from Operations reached 11024000.0 in Q4 2024 per SGMT's latest filing, up from 19569000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 3879000.0 in Q3 2023 and bottomed at 19569000.0 in Q3 2024.